For example, the use of drugs to target the protein product of the BCR–ABL translocation in chronic myeloid leukemia, or the BRAF gene in malignant melanoma, helped transform the treatment of these diseases and substantially improve survival rates [3, 4]. The gene discussed is BRAF; the disease is melanoma.